Related Experiment Videos
Failure to detect mutations in the retinoblastoma protein-binding domain of the transcription factor E2F-1 in human
T Nakamura1, Y Monden, K Kawashima
1Laboratory of Cancer Research, Banyu Tsukuba Research Institute in collaboration with Merck Research Laboratories, Tsukuba, Ibaraki.
Abstract:
The functions of the transcription factor E2F-1 are regulated by the RB protein through the RB-binding domain of E2F-1 and this factor is considered to be an important molecule that functions downstream of the RB protein. In order to determine whether E2F-1 that cannot bind to RB might be associated with various human cancers, we searched for mutations in the RB-binding domain of E2F-1 using samples of DNA from various clinical specimens obtained from 406 cancer patients (with lung, pancreatic, stomach, colon, esophageal, and hepatic cancers) by analysis of polymerase chain reaction-mediated single-strand conformational polymorphism. No mutations or deletions were detected in genes for E2F-1 from any of the tumor tissues examined. These results suggest that a mutation or deletion in E2F-1 that might affect binding of the RB protein is not involved in human cancers.
Insights
Mutations in the E2F-1 gene
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- The RB protein regulates transcription factor E2F-1 activity via its RB-binding domain.
- E2F-1 is a key molecule functioning downstream of the RB protein.
Purpose of the Study:
- To investigate mutations in the RB-binding domain of E2F-1 in human cancers.
- To determine if impaired RB binding in E2F-1 is associated with cancer development.
Main Methods:
- Analysis of polymerase chain reaction-mediated single-strand conformational polymorphism (PCR-SSCP).
- Screening of the RB-binding domain of E2F-1 in DNA from 406 cancer patients.
- Examination of tumor tissues from lung, pancreatic, stomach, colon, esophageal, and hepatic cancers.
Main Results:
- No mutations or deletions were detected in the E2F-1 gene's RB-binding domain.
- The examined tumor tissues showed no alterations in E2F-1 related to RB binding.
Conclusions:
- Mutations or deletions in E2F-1 affecting RB protein binding are not implicated in the studied human cancers.
- The RB-binding domain of E2F-1 does not appear to be a common site for cancer-associated mutations.